Announcements Trials

Browse Landscape

Phase

Phase NA 10 Phase EARLY_PHASE1 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 10 Genitourinary 6 Gastrointestinal 5 Other hematologic neoplasm 3 Lymphoid 2 Thoracic 1 Head & Neck 1 Dermatologic 1 CNS 1

Conditions

Melanoma 862 Lymphoma, T-Cell, Cutaneous 143 Uveal Melanoma 97 Skin Neoplasms 96 Mycosis Fungoides 95 Sezary Syndrome 81 Carcinoma, Basal Cell 76 Neoplasm Metastasis 68 Lymphoma 64 Lymphoma, Non-Hodgkin 63 Keratosis, Actinic 61 Neoplasms 57 Leukemia, Lymphocytic, Chronic, B-Cell 57 Carcinoma, Renal Cell 55 Carcinoma, Non-Small-Cell Lung 54 Lymphoma, B-Cell, Marginal Zone 53 Precursor Cell Lymphoblastic Leukemia-Lymphoma 52 Lymphoma, Mantle-Cell 52 Lymphoma, Large B-Cell, Diffuse 52 Lymphoma, Follicular 52 Hodgkin Disease 52 Lymphoma, Large-Cell, Immunoblastic 50 Carcinoma, Merkel Cell 50 Burkitt Lymphoma 49 Brain Neoplasms 46 Multiple Myeloma 44 Lymphoma, Large-Cell, Anaplastic 41 Recurrence 40 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 40 Breast Neoplasms 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Motor Activity × Dermatologic × Clear all

NCT03171064 2023-05-11

Sportivumab

University Hospital Heidelberg

Phase 2 Completed

Melanoma, Motor Activity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡